Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cell Immunotherapy Firm Adicet Launches

by Lisa M. Jarvis
February 1, 2016 | A version of this story appeared in Volume 94, Issue 5

Cell-immunotherapy-focused Adicet Bio has launched with $51 million in its first round of financing led by OrbiMed and including Novartis Venture Fund and Pontifax. In clinical trials, its cellular therapies reengineer a patient’s own T cells to home in on and kill cancer cells. Those highly personalized treatments present manufacturing challenges and may prove to be expensive. Adicet is also working on universal immune cell therapies, which would allow multiple patients to be treated. Adicet also announced the acquisition of Applied Immune Technologies, which is developing immunotherapies that target the intracellular proteome.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.